Compare IDEXX Laboratories, Inc. (IDXX) vs Lumen Technologies Inc (LUMN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Lumen Technologies Inc — how do they compare? IDEXX Laboratories, Inc. trades at $563.81 (market cap $44.48B), while Lumen Technologies Inc trades at $6.76 (market cap $6.47B). The key difference: IDEXX Laboratories, Inc. is far larger — about 6.9× Lumen Technologies Inc's market cap, and Lumen Technologies Inc is trading nearer its 52-week high, IDEXX Laboratories, Inc. nearer its low. Which is the better fit depends on your goals.
| IDXX | LUMN | |
|---|---|---|
Market Cap | $44.48B | $6.47B |
Sector | Health | Media |
52-Week High | $766.68 | $11.83 |
52-Week Low | $520.87 | $3.70 |
Enterprise Value | $45.38B | $18.10B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories trades at $552.46, down 2.64% today, with neutral technical signals but strong fundamental performance. The company maintains robust profitability with 24.63% net margins and has beaten earnings expectations for three consecutive quarters. Recent news highlights AI integration in medical devices and upcoming Q2 2026 results on August 4, 2026. The stock shows consistent revenue growth from $3.4B in 2022 to $4.3B in 2025.
Outlook remains positive given earnings momentum and analyst consensus, though elevated valuation ratios (P/E 41.49) pose risks. Key catalysts include Q2 earnings release and continued AI adoption in veterinary diagnostics. Primary risks involve competitive pressures and market volatility affecting premium valuations.
LUMN trades at $6.76, up 7.64% today, but remains in a bearish technical trend with resistance at $7. The company reported a net loss of $1.74B in 2025 despite beating EPS estimates in two of the last three quarters. Recent news highlights AI-focused initiatives, including the acquisition of Alkira and recognition in Gartner's AI vendor report, signaling strategic repositioning amid declining revenue.
The outlook is cautious with high debt ($17.49B long-term) and negative profitability metrics posing significant risks. Analyst consensus is mixed (14% Buy, 61% Hold) with a $8.25 price target, suggesting limited upside. Investors should weigh cost-cutting progress and AI contract growth against persistent cash flow challenges and competitive pressures in telecom services.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Lumen Technologies Inc
With 450,000 route miles of fiber, including over 35,000 route miles of subsea fiber connecting Europe, Asia, and Latin America, Lumen Technologies is one of the United States' largest telecommunications carriers serving global enterprises. Its merger with Level 3 further shifted the company's operations toward businesses (over 70% of revenue) and away from its legacy consumer business. Lumen offers businesses a full menu of communications services, providing colocation and data center services, data transportation, and end-user phone and internet service. On the consumer side, Lumen provides broadband and phone service across 37 states, where it has 4.5 million broadband customers.
Read more on LUMN →
